Literature DB >> 8332922

Cost-effectiveness league tables: more harm than good?

M Drummond1, G Torrance, J Mason.   

Abstract

In recent years it has become fashionable to make comparisons (in 'league tables' or rankings) between health care interventions in terms of their relative cost-effectiveness, in cost per life-year or cost per quality-adjusted life-year gained. However, concerns have been raised about the unthinking use of league tables and some authors have questioned the theoretical basis of their construction. In this paper a recently-reported league table is scrutinized and the important methodological features of the source studies identified. These include the choice of discount rate, the method of estimating utility values for health states, the range of costs and consequences considered and the choice of comparison programme. Several recommendations are made for improvements, both in the methodology of economic evaluation studies and in the construction and use of league tables. It is concluded that, for league tables to be useful, decision makers should be able to assess the relevance and reliability of the evidence in their own setting. Fuller reporting of methods and results by the authors of economic evaluation studies would greatly assist in the appropriate construction and use of league tables.

Mesh:

Year:  1993        PMID: 8332922     DOI: 10.1016/0277-9536(93)90315-u

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  43 in total

1.  Culture, self-rated health and resource allocation decision-making.

Authors:  V L Wiseman
Journal:  Health Care Anal       Date:  1999

Review 2.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

3.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

4.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

Authors:  B George; A Harris; A Mitchell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Random vs. nonrandom mixing in network epidemic models.

Authors:  Gregory S Zaric
Journal:  Health Care Manag Sci       Date:  2002-04

7.  Cost-utility analysis: use QALYs only with great caution.

Authors:  Maurice McGregor
Journal:  CMAJ       Date:  2003-02-18       Impact factor: 8.262

8.  A risk-adjusted approach to comparing the return on investment in health care programs.

Authors:  Pedram Sendi; Maiwenn J Al; Heinz Zimmermann
Journal:  Int J Health Care Finance Econ       Date:  2004-09

Review 9.  Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.

Authors:  Stephen M Beard; Lucy Wall; Louise Gaffney; Fiona Sampson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.